Sign In
Buy ISEE
$39.95
+0 (+0%)
At Close: Oct 09, 2023
Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration
09:26am, Friday, 18'th Jun 2021
Iveric Bio Inc (NASDAQ: ISEE) has shared the new post-hoc analyses of GATHER1 and the progress of GATHER2 clinical trials evaluating Zimura (avacincaptad pegol) for geographic atrophy (G.A.) second
NEW YORK--(BUSINESS WIRE)--Iveric Bio will present data on Zimura GATHER2 and new GATHER1 post-hoc analyses at its Dry Age-Related Macular Degeneration Virtual Symposium.
Iveric Bio to Host Investor Symposium on Dry Age-Related Macular Degeneration on June 18, 2021
07:30am, Wednesday, 09'th Jun 2021
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium on June 18, 2021, from 10:00 a.m. to 12:00 p.m. ET.
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2021 Results - Earnings Call Transcript
03:12pm, Wednesday, 05'th May 2021
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2021 Results - Earnings Call Transcript
New Strong Sell Stocks for April 26th
10:31am, Monday, 26'th Apr 2021
ARR, GMDA, ISEE, LMB, and LIQT have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2021
New Strong Sell Stocks for April 21st
10:31am, Wednesday, 21'st Apr 2021
EXTN, PSXP, ISEE, OR, and QIWI have been added to the Zacks Rank #5 (Strong Sell) List on April 21, 2021
New Strong Sell Stocks for April 6th
12:07pm, Tuesday, 06'th Apr 2021
JOBS, BUD, EURN, ISEE, and KL have been added to the Zacks Rank #5 (Strong Sell) List on April 6, 2021
David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund
06:45am, Monday, 05'th Apr 2021
NEW YORK--(BUSINESS WIRE)--Iveric Bio today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years.
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Thursday, 01'st Apr 2021
NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2020 Results - Earnings Call Transcript
11:03am, Wednesday, 03'rd Mar 2021
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2020 Results - Earnings Call Transcript
Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results
06:30am, Wednesday, 03'rd Mar 2021
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2020 and provided a general business update.
Iveric Bio to Present at the Cowen 41st Annual Health Care Conference
08:00am, Thursday, 25'th Feb 2021
NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that Glenn Sblendorio, CEO, and Pravin Dugel, CSO, CBO, will participate in a fireside chat at the Cowen Conference on March 4.
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript
01:49pm, Monday, 02'nd Nov 2020
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript
4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29)
08:09am, Monday, 26'th Oct 2020
Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund takes a lo
Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com
12:00am, Friday, 25'th Sep 2020
The
